SNAP-8 vs Liraglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
SNAP-8
SNAP-8 (Acetyl Octapeptide-3) is a cosmetic peptide that reduces the appearance of wrinkles by modulating muscle contraction. It is often called 'topical Botox' though it works through a different mechanism.
Full details →Liraglutide
Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.
Full details →Side-by-Side Comparison
| Aspect | SNAP-8 | Liraglutide |
|---|---|---|
| Mechanism | Mimics the N-terminal end of SNAP-25, competing with native SNAP-25 for position in the SNARE complex. This reduces neurotransmitter release at the neuromuscular junction, decreasing muscle contraction. | Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects. |
| Typical Dosage | Topical: 3-10% concentration in serums or creams, applied 1-2 times daily to target areas (forehead, crow's feet, etc.). | Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily. |
| Administration | Topical application only. Should be applied to clean skin. Often formulated with penetration enhancers for better absorption. | Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications. |
| Side Effects | Generally well-tolerated topically. Rare reports of mild skin irritation. No systemic effects at cosmetic doses. | Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use. |
| Best For |